A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

According to recent statistics, Blacks are twice as likely to develop multiple myeloma as other ethnicities. To make matters worse, they also have a higher mortality rate when it comes to this form of ...

As the authors reported in Radiology Case Reports, the patient had no history of cancer and had no pain, weakness, numbness, ...

Supported in part by the GSRT Operational Program “Competitiveness, Entrepreneurship, & Innovation (EPAnEK) 2014-2020.” Presented in part in the 61st American Society of Hematology (ASH) annual ...

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma. Ciara Freeman, MD, PhD, a medical oncologist at Moffitt ...

“There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible. Anito-cel has the unique potential to address ...

Abstract: This paper presents a deep learning approach for the classification of multiple skin diseases, leveraging the prowess of Convolutional Neural Networks (CNNs) and a dataset rich in ...

Background: Multiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. This study aims to describe the ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma. In this Community Case Forum ...

Background: Multiple myeloma (MM) is a biologically heterogeneous malignancy of clonal plasma cells, often progressing from MGUS or smoldering MM. It causes anemia, bone lesions, and immune ...

C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR ...